Opinion|Videos|February 3, 2025
Long-Term Outcomes with VMAT2 Inhibitors
Panelists discuss how long-term open-label extension studies of VMAT2 inhibitors demonstrated sustained efficacy and tolerability of both deutetrabenazine (ARM-TD and AIM-TD extensions showing durable response over 3 years) and valbenazine (KINECT 4 showing maintained improvements through 48 weeks), with low discontinuation rates due to adverse events and no new safety signals emerging during extended treatment periods.
Advertisement
Episodes in this series
Video series above is prompted by the following:
- What did the following open-label extension studies reveal about the long-term safety and efficacy of the following VMAT2 inhibitors?
- Deutetrabenazine
- Valbenazine
Advertisement
Related to this article
In an interview with Pharmacy Times, Ali A. Habib, MD, clinical professor of neurology at the University of California, Irvine, discusses what the hospitalization findings mean for patients and why they should be viewed as supportive evidence
Emergency and ICU pharmacists would be most likely to see pneumonic plague. An expert reviews first-line agents, alternatives, and postexposure prophylaxis.
A former residency program director unpacks why this debate keeps resurfacing, and why some reasons people give for skipping residency may not hold up the way they think they do.
The FDA approval of pritelivir offers an oral treatment for refractory HSV lesions in immunocompromised adults, with drug interactions creating an important role for pharmacists.
Weltruza, the first subcutaneous long-acting injectable (LAI) formulation of olanzapine, requires no loading doses, oral supplementation, or postinjection monitoring.
Eric Lawitz, MD, explains how pharmacists can raise liver risk with patients with obesity and why a FIB-4 score from routine blood work is a good first step.
Sometimes, a breakthrough matters not only because of what it does for patients today, but because of what it makes possible for tomorrow.
Pharmacogenomic-guided prescribing uses genetic data to protect patients from dangerous toxicities and get them the right drug at the right dose from the start.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves First Once-Monthly Subcutaneous Olanzapine LAI for Adults With Schizophrenia
2
Pneumonic Plague: What Pharmacists Need to Know About Treatment
3
Rising Gallbladder Complications With GLP-1 Receptor Agonists Call for Closer Pharmacist Monitoring
4
FDA Approves Pritelivir for Refractory HSV Lesions in Immunocompromised Adults
5